Cigna Group Rated as 'Buy' Amid Significant Undervaluation and Growth Prospects

Cigna Group (CI) is currently positioned as a compelling investment opportunity, trading at a forward P/E ratio of 8.5x, which represents a 29% discount to its estimated fair value. Analysts project that the company will resume double-digit adjusted income per share growth starting in 2027. Key catalysts for this expansion include the robust performance of its pharmacy segment and the increasing adoption of biosimilar medications. Furthermore, Cigna is expanding its footprint in behavioral health services while maintaining an aggressive strategy for share buybacks. With a disciplined capital deployment plan, the company is expected to deliver an annual total return of approximately 17% through 2031. This outlook underscores Cigna's potential as a value play within the healthcare sector, supported by strong long-term growth drivers.